Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy
- 23 August 2020
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (10), 2492-2496
- https://doi.org/10.1080/10428194.2020.1772472
Abstract
(2020). Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. Leukemia & Lymphoma. Ahead of Print.This publication has 14 references indexed in Scilit:
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA StudyJournal of Clinical Oncology, 2019
- Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaThe New England Journal of Medicine, 2018
- Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study GroupTransplantation and Cellular Therapy, 2018
- Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research AnalysisTransplantation and Cellular Therapy, 2018
- Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare StudyBritish Journal of Haematology, 2018
- When to treat patients with relapsed follicular lymphomaExpert Review of Hematology, 2017
- Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable AnalysisTransplantation and Cellular Therapy, 2016
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyJournal of Clinical Oncology, 2015
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008